Cure8 research brief
The study proposes a new immunomodulatory approach—phosphatidylserine liposomes—that reduced inflammation in mouse colitis models and altered monocyte and T-cell responses, which could point toward future therapies for Crohn’s disease if validated in humans.
Researchers in IBD immunology, translational drug developers, and clinicians interested in emerging monocyte-targeted treatments
The paper measures lower circulating phosphatidylserine (PS) in Crohn’s patients and shows that delivering PS as liposomes (PSL) improved weight, disease scores, and colon pathology in TNBS mouse models of acute and chronic colitis.
The authors link PSL’s effects to changes in monocyte populations (reducing pro-inflammatory Ly6C-high cells and increasing Ly6C-low patrolling cells), reduced Th17 responses, increased regulatory T cells, and activation of a TREM2/DAP12/p-STAT6 signaling pathway in mouse-derived monocytes.
The study is preclinical: experiments were done in mouse TNBS colitis models and in vitro with mouse bone marrow–derived monocytes. The findings indicate a mechanism and a candidate therapeutic approach, but do not demonstrate safety or efficacy in humans.
Posted preprint on Research Square with full-text abstract; findings are based on mouse models and in vitro mouse cell work. Not peer-reviewed clinical evidence.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
Researchers link a bacterial metabolic pathway (pdu/pduB) in AIEC to intestinal inflammation and show that host vitamin B12 availability can reduce bacterial invasion and colitis in mice—suggesting a modifiable host...
If AIEC contribute to Crohn’s disease for a given person, this study suggests host vitamin B12 levels and bacterial pdu pathway activity might influence bacterial invasion and inflammation — potentially pointing to new...
